Table 1.

Reported Compounds Currently in Development or Being Marketed^a

drug	effect on TRPV1	condition	phase
capsaicin	agonist	dysphagia, aspiration, swallow response, videofluoroscopy, sensorial neurostimulation	phase 2
resiniferatoxin	agonist	pain/cancer	phase 1
intrathecal resiniferatoxin	agonist	pain, intractable	phase 2
civamide nasal spray	agonist	dry eye	phase 2
civamide nasal solution	agonist	episodic cluster headache	phase 3
30% mannitol in vehicle cream	antagonist	pain	efficacy study
JNJ-39439335	antagonist	pain	phase 1
SYL1001	antagonist	ocular pain	phase 1
AZD1386	antagonist	pain	phase 2
DWP05195	antagonist	postherpetic neuralgia	phase 2
SB-705498	antagonist	migraine, acute	phase 2
SB-705498	antagonist	toothache	phase 2
SB-705498	antagonist	nonallergic rhinitis	phase 2
SB-705498	antagonist	dermatitis, atopic	phase 1
SB-705498	antagonist	irritable colon, fecal urgency, irritable bowel syndrome	phase 2
XEN-D0501	antagonist	chronic obstructive pulmonary disease	phase 2
XEN-D0501	antagonist	chronic idiopathic cough	phase 2

^aThese data are from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.